{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:47:18Z","timestamp":1761598038788,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.nefro.2018.10.008","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T14:56:37Z","timestamp":1549810597000},"page":"269-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis"],"prefix":"10.1016","volume":"39","author":[{"given":"Yan-Chun","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Mei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2018.10.008_bib0190","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1523-1755.2002.00125.x","article-title":"Membranous nephropathy: quo vadis?","volume":"61","author":"Cattran","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2018.10.008_bib0195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.nefro.2018.10.008_bib0200","first-page":"35","article-title":"Natural history, clinical course and morphological evolution of membranous nephropathy","volume":"7","author":"Honkanen","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2018.10.008_bib0205","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2018.10.008_bib0210","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.1995.161","article-title":"A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group","volume":"47","author":"Cattran","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2018.10.008_bib0215","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2018.10.008_bib0220","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000368589","article-title":"Rituximab in primary membranous nephropathy: first-line therapy, why not?","volume":"128","author":"Cravedi","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nefro.2018.10.008_bib0225","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/13543784.16.7.1099","article-title":"Tacrolimus in the treatment of idiopathic nephrotic syndrome","volume":"16","author":"Westhoff","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.nefro.2018.10.008_bib0230","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Gupta","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2018.10.008_bib0235","first-page":"100","article-title":"Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients","volume":"35","author":"Faurschou","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefro.2018.10.008_bib0240","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000348475","article-title":"Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial","volume":"181","author":"Xu","year":"2013","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.nefro.2018.10.008_bib0245","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5301\/jn.5000199","article-title":"Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids","volume":"26","author":"He","year":"2013","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefro.2018.10.008_bib0250","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","article-title":"Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial","volume":"339","author":"Chen","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.nefro.2018.10.008_bib0255","first-page":"584","article-title":"Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria","volume":"21","author":"Li","year":"2008","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefro.2018.10.008_bib0260","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.nefro.2018.10.008_bib0265","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.nefro.2018.10.008_bib0270","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ekir.2017.02.004","article-title":"Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide","volume":"2","author":"Ramachandran","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefro.2018.10.008_bib0275","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial","volume":"21","author":"Ramachandran","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.nefro.2018.10.008_bib0280","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jfma.2015.07.021","article-title":"Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy","volume":"115","author":"Peng","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.nefro.2018.10.008_bib0285","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(88)92470-1","article-title":"Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function","volume":"2","author":"Mathieson","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.nefro.2018.10.008_bib0290","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrneph.2012.35","article-title":"Pathogenesis of membranous nephropathy: recent advances and future challenges","volume":"8","author":"Ronco","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefro.2018.10.008_bib0295","doi-asserted-by":"crossref","first-page":"6281054","DOI":"10.1155\/2018\/6281054","article-title":"Membranous nephropathy and anti-podocytes antibodies: implications for the diagnostic workup and disease management","volume":"2018","author":"Pozdzik","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.nefro.2018.10.008_bib0300","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1053\/j.ackd.2012.01.007","article-title":"Recent advances and prognosis in idiopathic membranous nephropathy","volume":"19","author":"Segal","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.nefro.2018.10.008_bib0305","first-page":"113","article-title":"[Practice guideline and trends for immunosuppressive treatment of glomerulonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis)]","volume":"59","author":"Podracka","year":"2013","journal-title":"Vnitr Lek"},{"key":"10.1016\/j.nefro.2018.10.008_bib0310","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1440-1797.2010.01427.x","article-title":"Treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: a single centre's retrospective study","volume":"16","author":"Yuan","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.nefro.2018.10.008_bib0315","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0272-6386(99)70138-1","article-title":"Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy","volume":"33","author":"Laluck","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2018.10.008_bib0320","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2018.10.008_bib0325","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/ndt\/gfi274","article-title":"Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus","volume":"21","author":"Sinha","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2018.10.008_bib0330","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.kint.2016.09.048","article-title":"Membranous nephropathy: integrating basic science into improved clinical management","volume":"91","author":"Cattran","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2018.10.008_bib0335","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.nefro.2018.10.008_bib0340","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.ajkd.2016.01.030","article-title":"Membranous nephropathy: a journey from bench to bedside","volume":"68","author":"Francis","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2018.10.008_bib0345","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2018.10.008_bib0350","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2014010091","article-title":"Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues","volume":"25","author":"Hofstra","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2018.10.008_bib0355","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2018.10.008_bib0360","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis","volume":"62","author":"Beck","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2018.10.008_bib0365","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/gfp390","article-title":"Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial","volume":"25","author":"Hofstra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2018.10.008_bib0370","doi-asserted-by":"crossref","first-page":"e0184398","DOI":"10.1371\/journal.pone.0184398","article-title":"Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: a network meta-analysis","volume":"12","author":"Song","year":"2017","journal-title":"PLOS ONE"}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:53:19Z","timestamp":1759323199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699519300116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0211699519300116"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2018.10.008","relation":{},"ISSN":["0211-6995"],"issn-type":[{"type":"print","value":"0211-6995"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2018.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}